Analysts forecast that AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) will report earnings of ($0.28) per share for the current quarter, according to Zacks. Three analysts have issued estimates for AcelRx Pharmaceuticals’ earnings, with estimates ranging from ($0.32) to ($0.23). AcelRx Pharmaceuticals reported earnings of ($0.24) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 16.7%. The company is expected to announce its next earnings results on Thursday, July 27th.

According to Zacks, analysts expect that AcelRx Pharmaceuticals will report full year earnings of ($1.12) per share for the current financial year, with EPS estimates ranging from ($1.24) to ($0.97). For the next fiscal year, analysts expect that the business will post earnings of ($0.84) per share, with EPS estimates ranging from ($1.29) to ($0.64). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for AcelRx Pharmaceuticals.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its quarterly earnings data on Monday, May 8th. The specialty pharmaceutical company reported ($0.34) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by $0.06. AcelRx Pharmaceuticals had a negative return on equity of 478.66% and a negative net margin of 273.65%. The business had revenue of $3.11 million for the quarter, compared to analysts’ expectations of $2.36 million.

Several equities analysts have weighed in on ACRX shares. Jefferies Group LLC restated a “buy” rating and set a $7.00 price target on shares of AcelRx Pharmaceuticals in a report on Friday, July 14th. Zacks Investment Research upgraded AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 target price for the company in a report on Wednesday, May 3rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. AcelRx Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $8.67.

Shares of AcelRx Pharmaceuticals (ACRX) traded up 12.70% during mid-day trading on Monday, reaching $3.55. The company’s stock had a trading volume of 1,486,327 shares. The stock’s market capitalization is $161.10 million. AcelRx Pharmaceuticals has a 12-month low of $1.95 and a 12-month high of $4.08. The company’s 50-day moving average price is $2.38 and its 200-day moving average price is $2.71.

In other news, major shareholder Life Sciences Maste Perceptive sold 875,000 shares of the business’s stock in a transaction on Monday, June 19th. The stock was sold at an average price of $2.40, for a total value of $2,100,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 28.10% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp increased its stake in AcelRx Pharmaceuticals by 6.6% in the first quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock valued at $355,000 after buying an additional 6,942 shares during the last quarter. ING Groep NV increased its stake in shares of AcelRx Pharmaceuticals by 200.0% in the first quarter. ING Groep NV now owns 39,000 shares of the specialty pharmaceutical company’s stock worth $123,000 after buying an additional 26,000 shares during the last quarter. Acadian Asset Management LLC increased its stake in shares of AcelRx Pharmaceuticals by 326.1% in the first quarter. Acadian Asset Management LLC now owns 41,927 shares of the specialty pharmaceutical company’s stock worth $132,000 after buying an additional 32,087 shares during the last quarter. Finally, Teachers Advisors LLC increased its stake in shares of AcelRx Pharmaceuticals by 14.6% in the fourth quarter. Teachers Advisors LLC now owns 66,715 shares of the specialty pharmaceutical company’s stock worth $173,000 after buying an additional 8,475 shares during the last quarter. Institutional investors and hedge funds own 30.32% of the company’s stock.

TRADEMARK VIOLATION WARNING: “-$0.28 EPS Expected for AcelRx Pharmaceuticals, Inc. (ACRX) This Quarter” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/07/24/0-28-eps-expected-for-acelrx-pharmaceuticals-inc-acrx-this-quarter.html.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Get a free copy of the Zacks research report on AcelRx Pharmaceuticals (ACRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.